Biotechnology company Rakuten Medical Inc announced on Wednesday that it has signed a biopharmaceutical contract manufacturing agreement with LOTTE Biologics, a South Korea-based company that operates integrated biologics facilities in the United States and South Korea.
This agreement is intended to strengthen Rakuten Medical's production capabilities for its oncology therapy, Alluminox platform-based photoimmunotherapy.
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supporting Rakuten Medical's global clinical development and future commercialisation.
Rakuten Medical's proprietary photoimmunotherapy technology is designed to selectively target cells in solid tumours, by combining cell-targeting moieties, such as antibodies, with light-activatable agents, enabling focal and selective destruction of solid tumour cells upon light exposure. The therapy is approved in Japan for recurrent head and neck cancer.
A global Phase 3 clinical trial is underway in the United States, Taiwan region and Japan, with plans to start treatment in Ukraine and Poland soon. Rakuten Medical also plans to initiate a Phase 1 clinical trial in Japan for other solid tumours beyond head and neck cancer this year.
Ascletis announces submission of US IND application for oral obesity combination therapy
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
PharmaLogic to acquire CDMO business and manufacturing facility from Lantheus
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
Charles River Laboratories to acquire Frontage bioanalysis and DMPK businesses for USD470m
UCB and Biogen report additional positive Phase 3 data for investigational lupus treatment